留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

2021年美国风湿病学会关于幼年特发性关节炎治疗指南解读

钟林庆 宋红梅

钟林庆, 宋红梅. 2021年美国风湿病学会关于幼年特发性关节炎治疗指南解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0377
引用本文: 钟林庆, 宋红梅. 2021年美国风湿病学会关于幼年特发性关节炎治疗指南解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0377
ZHONG Linqing, SONG Hongmei. Interpretation on the 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0377
Citation: ZHONG Linqing, SONG Hongmei. Interpretation on the 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0377

2021年美国风湿病学会关于幼年特发性关节炎治疗指南解读

doi: 10.12290/xhyxzz.2022-0377
基金项目: 

国家重点研发计划(2021YFC2702001,2016YFC0901500);北京市自然科学基金(L202050);北京协和医学院学科建设项目(XE0472220191025)

详细信息
    通讯作者:

    宋红梅,E-mail:songhm1021@hotmail.com

  • 中图分类号: R593.22;R725

Interpretation on the 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis

Funds: 

National Key Research and Development Program of China (2021YFC2702001, 2016YFC0901500)

  • 摘要: 为改善幼年特发性关节炎( juvenile idiopathic arthritis,JIA)患儿预后,继2019年发布的针对多关节型JIA、骶髂关节炎、附着点炎及JIA相关葡萄膜炎患儿的治疗指导后,2022年3月美国风湿病学会( American College ofRheumatology,ACR)发表了新的JIA治疗指南,内容包括药物治疗和非药物治疗两部分,其中药物治疗部分主要针对少关节型和全身型JIA( systemic JIA,sJIA)及颞颌关节炎。本文将对指南主要内容进行解读,以供临床医生借鉴和参考。
  • [1] Onel KB, Horton DB, Lovell DJ, et al.2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis:Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis[J]. Arthritis Rheumatol, 2022,74:553-569.
    [2] Onel KB, Horton DB, Lovell DJ, et al.2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis:Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging[J]. Arthritis Care Res (Hoboken), 2022, 74:505-520.
    [3] Ringold S, Angeles-Han ST, Beukelman T, et al.2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis:Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis[J]. Arthritis Rheumatol, 2019, 71:846-863.
    [4] Angeles-Han ST, Ringold S, Beukelman T, et al.2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis[J]. Arthritis Rheumatol, 2019, 71:864-877.
    [5] Zulian F, Martini G, Gobber D, et al.Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis[J]. Rheumatology (Oxford), 2003, 42:1254-1259.
    [6] Zulian F, Martini G, Gobber D, et al.Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis:a double-blind trial[J]. Rheumatology (Oxford), 2004, 43:1288-1291.
    [7] Eberhard BA, Sison MC, Gottlieb BS, et al.Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis[J]. J Rheumatol, 2004, 31:2507-2512.
    [8] Wallace CA, Huang B, Bandeira M, et al.Patterns of clinical remission in select categories of juvenile idiopathic arthritis[J]. Arthritis Rheum, 2005, 52:3554-3562.
    [9] Wallace CA, Giannini EH, Huang B, et al.American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis[J]. Arthritis Care Res (Hoboken), 2011, 63:929-936.
    [10] Consolaro A, Ruperto N, Bazso A, et al.Development and validation of a composite disease activity score for juvenile idiopathic arthritis[J]. Arthritis Rheum, 2009, 61:658-666.
    [11] McErlane F, Beresford MW, Baildam EM, et al.Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis[J]. Ann Rheum Dis, 2013, 72:1983-1988.
    [12] Tibaldi J, Pistorio A, Aldera E, et al., Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis[J]. Rheumatology (Oxford), 2020, 59:3505-3514.
    [13] Aikawa NE, Trudes G, Campos LM, et al.Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients[J]. Lupus, 2013, 22:1394-1398.
    [14] Toplak N, Subelj V, Kveder T, et al.Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis[J]. Clin Exp Rheumatol, 2012, 30:436-444.
    [15] Heijstek MW, Scherpenisse M, Groot N, et al.Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis:a prospective controlled observational cohort study[J]. Ann Rheum Dis, 2014, 73:1500-1507.
    [16] Heijstek MW, Kamphuis S, Armbrust W, et al.Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis:a randomized trial[J]. Jama, 2013, 309:2449-2456.
    [17] Uziel Y, Moshe V, Onozo B, et al.Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe:Multicenter, retrospective data collection[J]. Vaccine, 2020, 38:2198-2201.
  • 加载中
计量
  • 文章访问数:  13
  • HTML全文浏览量:  1
  • PDF下载量:  0
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-07-07
  • 录用日期:  2022-08-23
  • 网络出版日期:  2022-09-09

目录

    /

    返回文章
    返回

    【通知】尊敬的读者、作者及编者:因特殊原因,本站自2022.9.30至10.24日期间实施6—24点开放,其他时段访问受限,给您带来不便敬请谅解!10.25日恢复如常。